OPNT News and Press, Opiant Pharmaceuticals Inc. From 11/14/22

Indivior To Acquire Opiant Pharmaceuticals PR Newswire Acquisition Strengthens and Extends Indivior's Position as a Leader in Addiction Treatment Opiant Pipeline Anchored by OPNT003, an Opioid Overdose Treatment with Clinically Demonstrated Characteristics Well...

SANTA MONICA, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant” or “Company”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced it will report its...

SANTA MONICA, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (Opiant) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced that the last patient has been enrolled in the Phase 2 clinical t...

SANTA MONICA, Calif., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (Opiant) (NASDAQ: OPNT) today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for Opiant’s pipeline candidate OPNT004 (drinabant) for the tr...

Opiant Pharmaceuticals, Inc. (OPNT) Q2 2022 Earnings Conference Call August 11, 2022 04:30 PM ET Company Participants Ben Atkins - VP Communications and Investor Relations Roger Crystal - President, Chief Executive Officer David O’Toole - Chief Financial O...

MindMed Strengthens Board with Appointment of Two New Independent Directors Canada NewsWire NEW YORK , Aug. 12, 2022 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company"), a clinical stage biopharmaceutical company developing novel pr...

Opiant Pharmaceuticals press release ( NASDAQ: OPNT ): Q2 GAAP EPS of -$2.31 misses by $0.95 . Revenue of $3.89M (-65.5% Y/Y) misses by $0.77M . For further details see: Opiant Pharmaceuticals GAAP EPS of -$2.31 misses by $0.95, revenue of $3.89M misses b...

SANTA MONICA, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three months and six mon...

Major earnings expected after the bell on Thursday include: Illumina ( ILMN ) Rivian Automotive ( RIVN ) Sandstorm Gold Ltd. ( SAND ) Vermilion Energy ( VET ) Wheaton Precious Metals Corp. ( WPM ) For further details see: Notable earnings ...

Opiant Pharmaceuticals ( NASDAQ: OPNT ) on Monday said it had been awarded an additional $2.1M of funding by the U.S. Biomedical Advanced Research and Development Authority (BARDA) to support the development of its opioid overdose nasal treatment OPNT003. Despite ...